LYSOGENE
Created in 2009
- BETA
Probably non active (C)
Several signals show that this company is not active anymore Social networks
1,094 5,281Activities
Technologies
Entity types
Location
18 Rue Jacques Dulud, 92200 Neuilly-sur-Seine, France
Neuilly-sur-Seine
France
Employees
Scale: 11-50
Estimated: 10
SIREN
613234129Engaged corporates
8
6 0Added in Motherbase
6 years, 1 month ago
biotech Value proposition
Improve the lives of children with CNS diseases
Lysogene is a biopharmaceutical gene therapy company with lead programs in neurodegenerative lysosomal storage disorders that affect children.
Founded in 2009 by Karen Aiach, whose own child was affected by a neurodegenerative disease, Lysogene is rooted in a deep and compassionate understanding of the impact these diseases have on patients and families. Karen’s personal experience fuels her determination to deliver real solutions that will improve patient outcomes and enhance quality of life for both patients and caregivers.
Over the past 10 years, Lysogene has acquired deep experience in developing gene therapies—from early discovery through the clinical, registration and review phases. Our strong science and execution track record has been validated by our partnership with Sarepta Therapeutics and the support of top-tier investors, with nearly $100m raised since inception.
More information about LYSOGENE at: www.lysogene.com
Gene Therapy, Central Nervous System Pathology, Lysosomal Storage Disease, and AAV vectorOriginal language
Pioneering gene therapies for CNS disorders
Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system (CNS). Since 2009, the company has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A pivotal clinical trial in MPS IIIA and a phase 1-2 clinical trial in GM1 Gangliosidosis are in preparation. Lysogene is also collaborating with a major partner to define the strategy of development for the treatment of Fragile X syndrome, a genetic disease related to autism.
More information about LYSOGENE at: www.lysogene.com
Lysogene – Delivering Gene Therapy’s Promise
https://lysogene.com/ - Website is disabled or domain is for sale
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Pfizer Pharmaceutical, Pharmaceutical Manufacturing | Pfizer Pharmaceutical, Pharmaceutical Manufacturing | Other 20 Jun 2019 | | |
 La French Tech Media, Government Administration | La French Tech Media, Government Administration | Other 10 Apr 2019 | | |
 BioValley France Public business cluster, Biotechnology, French Cluster, Biotechnology Research | BioValley France Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Not capitalistic Partnership Not event 25 Apr 2018 | | |
 Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Other 14 Sep 2018 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 10 Oct 2016 | | |
 Euronext Finance, Financial Services | Euronext Finance, Financial Services | Not capitalistic Not partnership Event 8 Feb 2017 | | |
 Societe Generale Bank, Banking | Societe Generale Bank, Banking | Other 13 Nov 2017 | | |
 SATT CONECTUS Research, Research Services | SATT CONECTUS Research, Research Services | Not capitalistic Partnership Not event 11 Jun 2021 | | |